Form 4: Director Jack Kaye Executes uniQure Stock Option Plan

Director Jack Kaye exercised options and sold 2,645 shares of uniQure N.V. under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Director Jack Kaye exercised options for 2,645 ordinary shares at a strike price of $16.04.
• Following the exercise, the director sold the same 2,645 shares at a market price of $30.01.
• The transactions were executed on June 3, 2026, pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025.
• The director's total beneficial ownership in uniQure N.V. stands at 20,439 ordinary shares post-transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was pre-planned and represents routine equity management by a director.

Positives

• The transaction was conducted under a pre-established Rule 10b5-1 plan, indicating a systematic approach to equity management rather than reactive selling.

Negatives

• The director reduced their direct holdings in the company by 2,645 shares.

Risks

• None identified in this specific filing.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is standard corporate practice for executives and directors to manage personal liquidity and is generally not indicative of a change in sentiment regarding company performance.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard industry practice for corporate insiders to avoid potential conflicts of interest or accusations of insider trading.
• The volume of shares sold represents a small fraction of the director's total holdings, which is consistent with typical portfolio rebalancing.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was executed via a pre-arranged plan.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

uniQure, QURE, Insider Trading, Form 4, Biotech, Equity Compensation